A new vaccine has been shown to reduce the risk of skin cancer recurrence by nearly half. - The vaccine targets melanoma, the deadliest form of skin cancer.
- Clinical trials showed a 44% lower risk of recurrence when combined with standard treatment. - The vaccine trains the immune system to attack patient-specific cancer cells.
Researchers are planning larger trials to confirm the results, which could lead to a new standard of care for melanoma patients.